Henrick Zetterberg, MD, PhD, of the University of Gothenburg discusses the exciting progress in recent years, from his group and others, on the development of blood biomarkers, which could help deliver treatment to patients earlier and save neurons. Zetterberg’s team studies many neurological diseases in addition to Alzheimer’s. He describes how technological advances have improved the detection of circulating biomarkers at very low levels, and how that information is being used diagnostically and therapeutically . . .